Evelo Biosciences, an early-stage biotech developing microbial gut therapies for inflammatory diseases, raised $85 million by offering 5.3 million shares at $16, within the range of $15 to $17. Evelo Biosciences plans to list on the Nasdaq under the symbol EVLO. Morgan Stanley, Cowen & Company and BMO Capital Markets acted as lead managers on the deal.
